AI Article Synopsis
- Quiescence in hematopoietic stem cells (HSCs) is essential for maintaining a reserve of cells that can quickly expand when needed, particularly in response to stress.
- Thrombopoietin (THPO) is known to support quiescent HSCs while also stimulating their metabolism and differentiation, though how it manages the balance between promoting cell proliferation and maintaining quiescence is still unclear.
- The study suggests the existence of a THPO-independent HSC subpopulation with low mitochondrial activity that can revert to a quiescent state and regain stem cell functionality when exposed to certain stimuli.
Article Abstract
Cell cycle quiescence is a fundamental property of hematopoietic stem cells (HSCs). Quiescent HSCs form a healthy pool of cells that serve as a reserve for massive HSC expansion under various conditions of stress. We previously reported that thrombopoietin (THPO) maintains quiescent HSCs and stimulates mitochondrial metabolism, megakaryocyte-lineage differentiation, and proliferation of HSCs. The underlying mechanism by which THPO balances its contradictory effect of promoting proliferation or quiescence on HSCs remains unknown. This review explores the role of THPO signaling in HSC differentiation and quiescence regulation. We present our data, which suggests that a THPO-independent HSC subpopulation sustaining a low mitochondrial metabolic profile reverts to quiescence and regains stem cell potential with external stimuli. There is a possibility that THPO-independent HSCs form a non-quiescent reserve HSC pool from which quiescent HSCs originate in the adult bone marrow.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.11406/rinketsu.62.521 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cdc42 is crucial for the early regulation of hepatic stellate cell activation.
Am J Physiol Cell Physiol
January 2025
Department of Anatomy and Regenerative Biology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
The activation of hepatic stellate cells (HSCs) from a quiescent state is a cause of liver fibrosis and a therapeutic target. HSCs are resident mesenchymal cells located in the space of Disse, exhibiting specialized morphological characteristics such as a stellate shape, large lipid droplets, and direct adhesions to hepatocytes via microprojections called HSC spines. Morphological alterations in HSCs play a crucial role in initiating their activation.
View Article and Find Full Text PDFEffective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates.
Leukemia
January 2025
Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.
Refractory disease and relapse are major challenges in acute myeloid leukemia (AML) therapy attributed to survival of leukemic stem cells (LSC). To target LSCs, antibody-drug conjugates (ADCs) provide an elegant solution, combining the specificity of antibodies with highly potent payloads. We aimed to investigate if FLT3-20D9h3-ADCs delivering either the DNA-alkylator duocarmycin (DUBA) or the microtubule-toxin monomethyl auristatin F (MMAF) can eradicate quiescent LSCs.
View Article and Find Full Text PDFThe adiponectin-PPARγ axis in hepatic stellate cells regulates liver fibrosis.
Cell Rep
January 2025
Touchstone Diabetes Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address:
Hepatic stellate cells (HSCs) are key drivers of local fibrosis. Adiponectin, conventionally thought of as an adipokine, is also expressed in quiescent HSCs. However, the impact of its local expression on the progression of liver fibrosis remains unclear.
View Article and Find Full Text PDFHepatic stellate cell single cell atlas reveals a highly similar activation process across liver disease aetiologies.
JHEP Rep
January 2025
Vrije Universiteit Brussel, Liver Cell Biology research group, Laarbeeklaan 103, 1090 Brussel, Belgium.
Article Synopsis
- This research explores the activation of hepatic stellate cells (HSCs) across different types of chronic liver disease (CLD), finding that their activation follows similar mechanisms regardless of the injury type.
- A single-cell RNA-sequencing atlas was created to categorize HSCs into three profiles: quiescent, initiatory, and myofibroblasts, indicating consistent activation patterns in both mice and humans.
- The study highlights key transcription factors and novel ligands involved in HSC activation, paving the way for new insights and potential treatments for liver fibrosis.
Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells.
Cell Stem Cell
December 2024
Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Harvard Stem Cell Institute, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA. Electronic address:
Gene editing the BCL11A erythroid enhancer is a validated approach to fetal hemoglobin (HbF) induction for β-hemoglobinopathy therapy, though heterogeneity in edit allele distribution and HbF response may impact its safety and efficacy. Here, we compare combined CRISPR-Cas9 editing of the BCL11A +58 and +55 enhancers with leading gene modification approaches under clinical investigation. Dual targeting of the BCL11A +58 and +55 enhancers with 3xNLS-SpCas9 and two single guide RNAs (sgRNAs) resulted in superior HbF induction, including in sickle cell disease (SCD) patient xenografts, attributable to simultaneous disruption of core half E-box/GATA motifs at both enhancers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!